Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xilio Therapeutics, Inc.
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
June 13, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
April 01, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 28, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
January 08, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
December 07, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 09, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
November 03, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
October 31, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
September 05, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
August 14, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
August 03, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
May 25, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
May 09, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at Upcoming Investor Conferences
February 27, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
February 16, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
February 02, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
November 23, 2022
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
November 09, 2022
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
November 04, 2022
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pricing of Initial Public Offering
October 21, 2021
From
Xilio Therapeutics, Inc.
Via
Business Wire
Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
October 18, 2021
From
Xilio Therapeutics, Inc.
Via
Business Wire
Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer
October 12, 2021
From
Xilio Therapeutics, Inc.
Via
Business Wire
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
September 16, 2021
From
Xilio Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.